KEBAI BILLS: Open Payments
NPI 1750342952 · POCATELLO, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$682 in 36 payments from 11 companies in 2025. Trend: 2023 $435 · 2024 $754 · 2025 $682
Food & beverage: $682
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 12 | $170 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $111 |
| Axsome Therapeutics, Inc. | 3 | $72 |
| ABBVIE INC. | 3 | $57 |
| Alkermes, Inc. | 3 | $52 |
| E.R. Squibb & Sons, L.L.C. | 3 | $51 |
| Vanda Pharmaceuticals Inc. | 2 | $44 |
| Otsuka America Pharmaceutical, Inc. | 2 | $42 |
| Janssen Pharmaceuticals, Inc | 2 | $41 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
Products named: CAPLYTA, AUSTEDO XR, UZEDY, Auvelity, VRAYLAR, COBENFY, FANAPT, ABILIFY ASIMTUFII.
Industry payments across ID — which companies pay providers there.
